Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Transl Lung Cancer Res
.
2018 Sep;7(Suppl 3):S290-S293.
doi: 10.21037/tlcr.2018.07.11.
Authors
Giulio Metro
1
,
Massimo Di Maio
2
Affiliations
1
Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.
2
Medical Oncology, A.O. Ordine Mauriziano, Department of Oncology, University of Torino, Torino, Italy.
PMID:
30393625
PMCID:
PMC6193898
DOI:
10.21037/tlcr.2018.07.11
No abstract available
Publication types
Editorial